How does Provenge work? This is a popular question, especially since Provenge (sipuleucel-T) is the first immunotherapy for prostate cancer. Provenge has demonstrated an ability to improve overall survival in men who have asymptomatic or minimally symptomatic prostate cancer that has spread and resisted treatment with hormone therapy. Therefore, it is natural for men to wonder,…
If you are wondering how to choose a prostate cancer treatment, there are several things you should know. Prostate cancer is one of the most common types of cancer that afflict American men, second only to skin cancer. According to the American Cancer Society, about one in six men will be diagnosed with the disease….
Will Medicare pay for cost of Provenge? That’s a question many men ask, especially since most of the men eligible for Provenge are age 65 or older. The high cost of healthcare is a major hurdle for many individuals and families, and so when the Food and Drug Administration (FDA) approved the first and only…
Provenge survival rates, also referred to as the overall survival benefit, have been reported as 4.1 months. This is the Provenge survival rates data upon which the Food and Drug Administration (FDA) granted its approval of Provenge for prostate cancer treatment. However, that figure may be low–by about twofold and possibly more. How could this be? For…
If Provenge treatment for advanced prostate cancer is a match for you, then your next step is to set up an appointment at a cell collection center. Provenge is intended for autologous use only, which means that your own blood cells are used to manufacture each dose of the drug. You will visit the cell collection center…
Provenge® (sipuleucel-T) is a unique treatment option for men who have asymptomatic or minimally symptomatic prostate cancer that has spread (metastasized) and also resisted hormone therapy (also referred to as metastatic castrate resistant or hormone refractory prostate cancer). Before the introduction of Provenge, men with this type of prostate cancer had no promising treatment opportunities….
Offering Provenge for low grade prostate cancer treatment is an option under consideration. Currently, Provenge (sipuleucel-T), the only immunotherapy for treatment of prostate cancer, has approval from the Food and Drug Administration (FDA) for use in men who have asymptomatic or minimally symptomatic advanced (metastatic) prostate cancer that has not responded to hormone therapy. In…
Provenge for early stage prostate cancer is not the approved use of this drug. In fact, when the immunotherapy Provenge (sipuleucel-T) was approved by the Food and Drug Administration (FDA) in 2010, it was limited to treatment of late stage prostate cancer. Specifically, it is for men with asymptomatic or minimally symptomatic metastatic prostate cancer that…
What is Provenge? If you have been diagnosed with prostate cancer, this is a question you might have on your list to ask your doctor. After all, you face some hard healthcare decisions, among which is choosing the type of treatment approach that best suits your situation. For men who have asymptomatic or minimally symptomatic…
Provenge information gathering can be challenging since this immunotherapy treatment for prostate cancer has been getting a lot of press lately. It can be difficult to wade through the rhetoric about what Provenge (sipuleucel-T) is, what it can and cannot do for men who have prostate cancer, and how to pay for treatment. So we…
Preparing for treatment with Provenge requires more steps than do other prostate cancer treatments. Let’s assume you, along with your healthcare team and your loved ones, have decided you are going to undergo treatment with Provenge. As you probably already know, Provenge (sipuleucel-T) is unlike all other drug treatments for prostate cancer: you don’t go…
